After deliberating, Goldman Sachs has decided to reinstate its buy rating on 4D Molecular Therapeutics (NASDAQ:FDMT). The renowned investment bank points to upcoming catalysts as the impetus behind its decision.

Goldman Sachs expressed optimism about the potential for shares to soar, underlining that the catalysts include 24-week data for 4D-150 in wet AMD and diabetic macular edema in the second half of the year. Additionally, the FDA’s feedback on aerosol 4D-710 in modulator ineligible/intolerant cystic fibrosis and modulator combinations in Q1, and data submission in Q2 to lift the clinical hold on 4D-310 in Fabry disease were cited as pivotal drivers.

Goldman revealed that it had constructed a model projecting approximately $7.5 billion in peak sales across six programs in 2032. The bank has set a price target of $81 for the stock.